Compare · CSTL vs UNH
CSTL vs UNH
Side-by-side comparison of Castle Biosciences Inc. (CSTL) and UnitedHealth Group Incorporated (UNH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CSTL and UNH operate in Medical Specialities (Health Care), so they compete in similar markets.
- UNH is the larger of the two at $386.95B, about 528.1x CSTL ($732.8M).
- UNH has been more active in the news (28 items in the past 4 weeks vs 9 for CSTL).
- UNH has more recent analyst coverage (25 ratings vs 6 for CSTL).
- Company
- Castle Biosciences Inc.
- UnitedHealth Group Incorporated
- Price
- -
- -
- Market cap
- $732.8M
- $386.95B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 9
- 28
- Recent ratings
- 6
- 25
Castle Biosciences Inc.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance program, and health care programs; medical and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical, as well as develops programs in areas, such as step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated has partnership with the University of California, San Francisco to expand the mental health workforce in California. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.
Latest CSTL
- Pres. & Chief Exec. Officer Maetzold Derek J exercised 550 shares at a strike of $2.39 and sold $95,622 worth of shares (4,172 units at $22.92) as part of a pre-agreed trading plan (SEC Form 4)
- Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
- Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
- Chief Operating Officer Oelschlager Kristen M sold $209,650 worth of shares (8,586 units at $24.42) as part of a pre-agreed trading plan, decreasing direct ownership by 28% to 21,874 units (SEC Form 4)
- Pres. & Chief Exec. Officer Maetzold Derek J sold $238,916 worth of shares (9,836 units at $24.29) as part of a pre-agreed trading plan and exercised 6,214 shares at a strike of $2.39 (SEC Form 4)
- SEC Form 144 filed by Castle Biosciences Inc.
- DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
- Roth Capital initiated coverage on Castle Biosciences with a new price target
- Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
- Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Latest UNH
- UnitedHealth upgraded by Robert W. Baird with a new price target
- UnitedHealth Group Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- UnitedHealth Group Reports Second Quarter 2026 Results
- UnitedHealthcare Launches New Spending Account Benefit, Putting More Choice in the Hands of Consumers
- Director Noseworthy John H was granted 206 shares, increasing direct ownership by 3% to 7,616 units (SEC Form 4)
- Director Montgomery Rice Valerie Md was granted 220 shares, increasing direct ownership by 3% to 7,876 units (SEC Form 4)
- Director Mcnabb Frederick William Iii was granted 250 shares, increasing direct ownership by 2% to 15,462 units (SEC Form 4)
- Director Gottlieb Scott was granted 210 shares, increasing direct ownership by 47% to 659 units (SEC Form 4)
- Director Gil Kristen was granted 206 shares, increasing direct ownership by 9% to 2,617 units (SEC Form 4)
- Director Garcia Paul R was granted 220 shares, increasing direct ownership by 6% to 3,906 units (SEC Form 4)